Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Company Overview - Apyx Medical Corporation is an advanced energy technology company focused on innovative products, including its Helium Plasma Platform Technology marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, demonstrating the company's commitment to clinical validation [3] Financial Results Announcement - Apyx Medical will release its financial results for the first quarter of fiscal year 2025 before markets open on Thursday, May 8th [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day to discuss the quarterly results and include a question-and-answer session [2] Investor Relations - The investor relations contact for Apyx Medical is Jeremy Feffer, Managing Director at LifeSci Advisors, who can be reached at 212-915-2568 or via email [3]